CoChat

New treatments in type 2 diabetes: a focus on the incretin‐based therapies

Open access
Barnett, Anthony H. · 2009 · Clinical Endocrinology
Cited by 49

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Summary: The demonstration that the incretin hormone glucagon‐like peptide 1 can improve glycaemic control in patients with type 2 diabetes has led to the rapid development during the last decade of promising new classes of agent for the management of type 2 diabetes. These agents possess a range of physiological effects that are associated with improved glycaemic control in diabetes including stimulation of glucose‐dependent insulin secretion, suppression of glucagon secretion, slowing of gastric emptying, and reduction of food intake. In addition, preclinical studies suggest that incretin‐based therapies may improve β‐cell function via enhancement of β‐cell mass and induction of genes important for differentiated β‐cell function. Exenatide, and the dipeptidyl peptidase‐4 inhibitors, sitagliptin and vildagliptin are already approved, and liraglutide is currently completing Phase 3 trials. As these agents and standard oral therapies for type 2 diabetes lower glucose levels through different, but potentially complementary mechanisms, their use in combination should provide effective, potentially additive, glycaemic control. The incretin‐based therapies also offer other advantages such as weight loss with exenatide and liraglutide, a reduced risk of hypoglycaemia, and as suggested by preclinical studies, a potential β‐cell preserving effect. Long‐term outcome and safety data are not available for these agents, but they appear generally well‐tolerated in comparison with existing therapies for type 2 diabetes. The multiple underlying glucose‐lowering actions of the incretin‐based therapies, as well as a lack of weight gain or even weight loss, make these important new additions to available antidiabetic agents expanding the treatment options available for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2008.03396.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 49

Metadata

Authors
Barnett, A. H.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2009-02-11
Volume
70
Issue
3
Pages
343-353
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2075073089
Cited by
49
References
29
FWCI
5.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New treatments in type 2 diabetes: a focus on the incretin‐based therapies. https://app.cochat.ai/papers/10.1111/j.1365-2265.2008.03396.x
The paper
Barnett, A. H. (2009). New treatments in type 2 diabetes: a focus on the incretin‐based therapies. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2008.03396.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.